Eli Lilly and 3M have stopped a clinical trial of their jointly developed genital herpes treatment Resiquimod because preliminary data showed that the drug was not effective, The Wall Street Journal reports. Earlier Phase II trials showed that the drug was safe and well-tolerated, but preliminary data from a Phase III human trial showed that the compound was not as effective as expected in prompting the immune system into attacking herpes virus in the body, in preventing herpes outbreaks, or in helping to prevent people carrying the virus from infecting others. The companies plan to further analyze the trial data to determine whether to conduct further studies of the compound.
Search
AI Powered
Human content,
AI powered search.
Latest Stories
Stay up to date with the latest in LGBTQ+ news with The Advocate’s email newsletter, in your inbox five days a week.
@ 2026 Equal Entertainment LLC.
All rights reserved
All rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
The Latest
Support Independent Journalism
LGBTQ+ stories deserve to betold.
Your membership powers The Advocate's original reporting—stories that inform, protect, and celebrate our community.
Become a Member
FOR AS LITTLE AS $5. CANCEL ANYTIME.
More For You
Most Popular
@ 2026 Equal Entertainment LLC. All Rights reserved














